417 related articles for article (PubMed ID: 10639689)
1. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone.
Scordo MG; Spina E; Facciolà G; Avenoso A; Johansson I; Dahl ML
Psychopharmacology (Berl); 1999 Dec; 147(3):300-5. PubMed ID: 10639689
[TBL] [Abstract][Full Text] [Related]
2. ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety.
Gunes A; Spina E; Dahl ML; Scordo MG
Ther Drug Monit; 2008 Oct; 30(5):628-33. PubMed ID: 18708991
[TBL] [Abstract][Full Text] [Related]
3. Effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia.
Yasui-Furukori N; Mihara K; Kondo T; Kubota T; Iga T; Takarada Y; De Vries R; Kaneko S; Tateishi T
J Clin Pharmacol; 2003 Feb; 43(2):122-7. PubMed ID: 12616663
[TBL] [Abstract][Full Text] [Related]
4. Risperidone plasma levels, clinical response and side-effects.
Riedel M; Schwarz MJ; Strassnig M; Spellmann I; Müller-Arends A; Weber K; Zach J; Müller N; Möller HJ
Eur Arch Psychiatry Clin Neurosci; 2005 Aug; 255(4):261-8. PubMed ID: 15565299
[TBL] [Abstract][Full Text] [Related]
5. Effects of various CYP2D6 genotypes on the steady-state plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, in Japanese patients with schizophrenia.
Mihara K; Kondo T; Yasui-Furukori N; Suzuki A; Ishida M; Ono S; Kubota T; Iga T; Takarada Y; de Vries R; Kaneko S
Ther Drug Monit; 2003 Jun; 25(3):287-93. PubMed ID: 12766554
[TBL] [Abstract][Full Text] [Related]
6. The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone.
Jovanović N; Božina N; Lovrić M; Medved V; Jakovljević M; Peleš AM
Eur J Clin Pharmacol; 2010 Nov; 66(11):1109-17. PubMed ID: 20563569
[TBL] [Abstract][Full Text] [Related]
7. Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes.
Yasui-Furukori N; Mihara K; Takahata T; Suzuki A; Nakagami T; De Vries R; Tateishi T; Kondo T; Kaneko S
Br J Clin Pharmacol; 2004 May; 57(5):569-75. PubMed ID: 15089809
[TBL] [Abstract][Full Text] [Related]
8. Physiologically Based Pharmacokinetic Modelling to Describe the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone According to Cytochrome P450 2D6 Phenotypes.
Kneller LA; Abad-Santos F; Hempel G
Clin Pharmacokinet; 2020 Jan; 59(1):51-65. PubMed ID: 31359271
[TBL] [Abstract][Full Text] [Related]
9. A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels.
Leon Jd; Susce MT; Pan RM; Wedlund PJ; Orrego ML; Diaz FJ
Pharmacopsychiatry; 2007 May; 40(3):93-102. PubMed ID: 17541883
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and bioequivalence evaluation of risperidone in healthy male subjects with different CYP2D6 genotypes.
Cho HY; Lee YB
Arch Pharm Res; 2006 Jun; 29(6):525-33. PubMed ID: 16833023
[TBL] [Abstract][Full Text] [Related]
11. Effect of the cytochrome P450 2D6*10 allele on risperidone metabolism in Japanese psychiatric patients.
Suzuki Y; Fukui N; Tsuneyama N; Watanabe J; Ono S; Sugai T; Saito M; Inoue Y; Someya T
Hum Psychopharmacol; 2012 Jan; 27(1):43-6. PubMed ID: 22745940
[TBL] [Abstract][Full Text] [Related]
12. Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients.
Jung SM; Kim KA; Cho HK; Jung IG; Park PW; Byun WT; Park JY
Clin Pharmacol Ther; 2005 Nov; 78(5):520-8. PubMed ID: 16321618
[TBL] [Abstract][Full Text] [Related]
13. Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients.
Roh HK; Kim CE; Chung WG; Park CS; Svensson JO; Bertilsson L
Eur J Clin Pharmacol; 2001 Nov; 57(9):671-5. PubMed ID: 11791898
[TBL] [Abstract][Full Text] [Related]
14. Effects of CYP2D6 and CYP3A5 genotypes on the plasma concentrations of risperidone and 9-hydroxyrisperidone in Korean schizophrenic patients.
Kang RH; Jung SM; Kim KA; Lee DK; Cho HK; Jung BJ; Kim YK; Kim SH; Han C; Lee MS; Park JY
J Clin Psychopharmacol; 2009 Jun; 29(3):272-7. PubMed ID: 19440082
[TBL] [Abstract][Full Text] [Related]
15. Serum concentrations and side effects in psychiatric patients during risperidone therapy.
Olesen OV; Licht RW; Thomsen E; Bruun T; Viftrup JE; Linnet K
Ther Drug Monit; 1998 Aug; 20(4):380-4. PubMed ID: 9712460
[TBL] [Abstract][Full Text] [Related]
16. Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6.
Kakihara S; Yoshimura R; Shinkai K; Matsumoto C; Goto M; Kaji K; Yamada Y; Ueda N; Ohmori O; Nakamura J
Int Clin Psychopharmacol; 2005 Mar; 20(2):71-8. PubMed ID: 15729081
[TBL] [Abstract][Full Text] [Related]
17. Impact of CYP2D6 Polymorphism on Steady-State Plasma Levels of Risperidone and 9-Hydroxyrisperidone in Thai Children and Adolescents with Autism Spectrum Disorder.
Vanwong N; Ngamsamut N; Medhasi S; Puangpetch A; Chamnanphon M; Tan-Kam T; Hongkaew Y; Limsila P; Sukasem C
J Child Adolesc Psychopharmacol; 2017 Mar; 27(2):185-191. PubMed ID: 26780783
[TBL] [Abstract][Full Text] [Related]
18. Impact of Ageing on Serum Concentrations of Risperidone and Its Active Metabolite in Patients with Known CYP2D6 Genotype.
Molden E; Waade RB; Hoff M; Haslemo T
Basic Clin Pharmacol Toxicol; 2016 Nov; 119(5):470-475. PubMed ID: 27145399
[TBL] [Abstract][Full Text] [Related]
19. Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia.
Wang L; Yu L; Zhang AP; Fang C; Du J; Gu NF; Qin SY; Feng GY; Li XW; Xing QH; He L
J Psychopharmacol; 2007 Nov; 21(8):837-42. PubMed ID: 17715206
[TBL] [Abstract][Full Text] [Related]
20. Impact of CYP2D6 genotype on steady-state serum concentrations of risperidone and 9-hydroxyrisperidone in patients using long-acting injectable risperidone.
Hendset M; Molden E; Refsum H; Hermann M
J Clin Psychopharmacol; 2009 Dec; 29(6):537-41. PubMed ID: 19910717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
